Xeris Pharmaceuticals, Inc. IPO Advisory
Share this IPO Profile:
Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
Xeris Pharmaceuticals, Inc. | XERS - NASDAQ |
$14.00-$16.00 |
$15.00 |
$15.75 | 5.7 million | 6/21/2018 |
Jefferies, Leerink Partners, RBC Capital, Mizuho Securities |
Co-Manager(s): |
Health Care |
Filing(s): Filed 2018-05-24 Terms Added 2018-06-11 Final Prospectus 2018-06-21
|
For IPO Boutique's "scale of 1 to 5" BUY rating on Xeris Pharmaceuticals, Inc. , and our comprehensive analysis, click "Buy Market Research".
Xeris Pharmaceuticals, Inc. Quote & Chart - Click for current quote -
XERS
About Xeris Pharmaceuticals, Inc. (adapted from Xeris Pharmaceuticals, Inc. prospectus):
They are a specialty pharmaceutical company leveraging their novel non-aqueous formulation technology platforms, XeriSol and XeriJect, to develop and commercialize ready-to-use injectable and infusible drug formulations.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "XERS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2024 IPO Boutique. All Rights Reserved